Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1021/acs.jproteome.0c00526 http://scihub22266oqcxt.onion/10.1021/acs.jproteome.0c00526 33347311!ä!33347311 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Proteome+Res 2021 ; 20 (1): 49-59 Nephropedia Template TP {{tp|p=33347311|t=2021. Overview of Targets and Potential Drugs of SARS-CoV-2 According to the Viral Replication |pdf=|usr=}}{{33347311}} gab.com Text Overview of Targets and Potential Drugs of SARS-CoV-2 According to the Viral Replication JO: J Proteome Res http://www.kidney.de/pget.php?&tw=1&pmid=33347311 #FOAvip Since the novel coronavirus pandemic, people around the world have been touched in varying degrees, and this pandemic has raised a major global health concern. As there is no effective drug or vaccine, it is urgent to find therapeutic drugs that can serve to deal with the current epidemic situation in all countries and regions. We searched drugs and response measures for SARS-CoV-2 in the PubMed database, and then updated the potential targets and therapeutic drugs from the perspective of the viral replication cycle. The drug research studies of the viral replication cycle are predominantly focused on the process of the virus entering cells, proteases, and RdRp. The inhibitors of the virus entry to cells and RdRp, such as Arbidol, remdesivir, favipiravir, EIDD-2081, and ribavirin, are in clinical trials, while most of the protease inhibitors are mainly calculated by molecular docking technology, which needs in vivo and in vitro experiments to prove the effect for SARS-CoV-2. This review summarizes the drugs targeting the viral replication process and provides a basis and directions for future drug development and reuse on the protein level of COVID-19. Twit Text FOAVip Overview of Targets and Potential Drugs of SARS-CoV-2 According to the Viral Replication ????J Proteome Res http://www.kidney.de/pget.php?&tw=1&pmid=33347311 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33347311 #FOAvip English Wikipedia <ref>{{Cite pmid|33347311}}</ref> Overview of Targets and Potential Drugs of SARS-CoV-2 According to the Viral Replication #MMPMID33347311 Zhang Y; Tang LV J Proteome Res 2021[Jan]; 20 (1): 49-59 PMID33347311show ga Since the novel coronavirus pandemic, people around the world have been touched in varying degrees, and this pandemic has raised a major global health concern. As there is no effective drug or vaccine, it is urgent to find therapeutic drugs that can serve to deal with the current epidemic situation in all countries and regions. We searched drugs and response measures for SARS-CoV-2 in the PubMed database, and then updated the potential targets and therapeutic drugs from the perspective of the viral replication cycle. The drug research studies of the viral replication cycle are predominantly focused on the process of the virus entering cells, proteases, and RdRp. The inhibitors of the virus entry to cells and RdRp, such as Arbidol, remdesivir, favipiravir, EIDD-2081, and ribavirin, are in clinical trials, while most of the protease inhibitors are mainly calculated by molecular docking technology, which needs in vivo and in vitro experiments to prove the effect for SARS-CoV-2. This review summarizes the drugs targeting the viral replication process and provides a basis and directions for future drug development and reuse on the protein level of COVID-19. |Angiotensin-Converting Enzyme 2/metabolism[MESH] |Animals[MESH] |Antiviral Agents/chemistry/*pharmacology[MESH] |Basigin/metabolism[MESH] |Coronavirus 3C Proteases/antagonists & inhibitors/metabolism[MESH] |Coronavirus Nucleocapsid Proteins/chemistry/metabolism[MESH] |Coronavirus RNA-Dependent RNA Polymerase/metabolism[MESH] |Dipeptidyl Peptidase 4/metabolism[MESH] |Furin/antagonists & inhibitors/metabolism[MESH] |Host-Pathogen Interactions/drug effects[MESH] |Humans[MESH] |SARS-CoV-2/*drug effects/pathogenicity/physiology[MESH] |Serine Endopeptidases/metabolism[MESH] |Small Molecule Libraries/pharmacology[MESH] |Spike Glycoprotein, Coronavirus/chemistry/metabolism[MESH]Overview of Targets and Potential Drugs of SARS-CoV-2 According to the(epmc).pdf DeepDyve Pubget Overpricing